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Ewing’s sarcoma accounts for a disproportionately high portion of the overall pediatric mortality rate compared to its rare
incidence in the pediatric population. Little progress has been made since the introduction of traditional chemotherapies, and
understanding the biology of the tumor is critical for developing new therapies. Ewing’s sarcomas rely on a functional vascular
supply, which is formed by a combination of angiogenesis and vasculogenesis. Recent insights into the molecular regulation of
bone marrow (BM) cell participation in vascular development have identiﬁed VEGF, SDF-1α, and DLL4 as critical players in the
vasculogenesis process. Clinical trials using vascular targeting agents, speciﬁcally targeting VEGF or DLL4, are underway.
1.Introduction
The current standard of care for Ewing’s sarcoma includes
a combination of preoperative and adjuvant chemotherapy
along with local control. Surgery is the preferred method
of local control, but in cases where surgical resection
is not possible, radiation therapy is used [1, 2]. First-
line chemotherapy includes a combination of ﬁve drugs:
vincristine, cyclophosphamide,doxorubicin,ifosfamide, and
etoposide [3]. This combination therapy achieves a nearly
70% survival rate for patients with nonmetastatic disease
[3]. It is presumed that the majority of patients with Ewing’s
sarcoma have metastatic disease at diagnosis. However, only
25% have detectable metastatic disease using conventional
diagnosticmethods.The outcomeofpatientswithmetastatic
disease continues to be poor, with less than 25% expected to
be long-term survivors [1, 3].
There is an urgent need for new therapeutic options
for patients with Ewing’s sarcoma, particularly for those
with metastatic disease, as cure rates have remained stagnant
for more than 20 years. The most signiﬁcant progress that
has been made is in using dose-intensive chemotherapy
which brings multiple toxicities with it [2–5]. A recent study
conducted by the Children’s Oncology Group demonstrated
an increase in event-free 3-year survival for patients with
nonmetastatic Ewing’s sarcoma by increasing the frequency
of chemotherapy. The event-free survival rate was 76% for
patients receiving chemotherapy every 2 weeks compared to
65% for patients given standard every-3-week chemother-
apy [6]. Understanding the biologic properties of Ewing’s
sarcoma and what is important in the microenvironment to
promote tumor growth will allow the identiﬁcation of more
targeted therapies outside of traditional chemotherapy.
The development of a functional vascular system is a
hallmark of solid tumors [7]. Ewing’s sarcomas, like other
solid tumors, are reliant on a functional vascular network
for the delivery of nutrients and oxygen and for the removal
of waste [8]. Therefore, one possible way to inhibit tumor
growth and promote tumor regression is by preventing the
tumorfromdevelopingavascular supply,essentially starving
the tumor of nutrients and oxygen. Deﬁning the molecular
mechanisms that direct blood vessel formation in Ewing’s
sarcoma is key to identifying therapeutic targets that might
prevent vascular development. This paper will provide a
comprehensive summary of the current understanding of
vasculogenesis in Ewing’s sarcoma and one of the processes2 Sarcoma
involved in blood vessel formation, as well as a brief review
of clinical trials using vascular targeting agents.
2.AngiogenesisandVasculogenesis
In most blood vessels, the lumen, or inner tube through
which blood ﬂows, is made up of a single layer of endothelial
cells. In arteries and veins, these endothelial cells are
surrounded by one or several layers of mural cells. Mural
cells include pericytes and vascular smooth muscle cells
(vSMCs). Varying amounts of connective tissue, including
collagen, elastic ﬁbers, and other proteins and polysaccha-
rides, are interspersed between the cells and surround blood
vessels.
At least two processes contribute to blood vessel forma-
tion in Ewing’s sarcoma: angiogenesis and vasculogenesis.
Angiogenesis is the sprouting of preexisting vessels to
form new ones. During angiogenesis, endothelial cells and
pericytes/vSMC proliferate and migrate, so that new blood
vessels would be formed by a locally derived cell population.
Alternatively, vasculogenesis is the process by which bone-
marrow-(BM-) derived precursor cells are recruited to sites
of developing vasculature and organized to form a vessel
network de novo. Vasculogenesis occurs during embryoge-
nesis and refers to the initial formation of the vasculature.
Originally, it was believed that postnatal vascular devel-
opment occurred only by angiogenesis. However, several
studieshavehighlighted the important role ofvasculogenesis
in postnatal processes such as the healing of cutaneous
wounds, in response to ischemia, and more recently, in
tumor growth [9–12]. Angiogenesis and vasculogenesis both
contribute to vascular growth in adults, and the level of
contribution of each varies based on the tissue and stimulus
[13]. In Ewing’s sarcoma, the vascular network is formed
by a combination of angiogenesis and vasculogenesis. BM-
derived cells within Ewing’s sarcoma vasculature were ﬁrst
reported by Bolontrade et al., who demonstrated that at
least 10% of blood vessels in Ewing’s sarcoma xenografts
contain one or more BM-derived endothelial cell [14]. This
wasshown using aBMtransplant modelthattakesadvantage
of MHC haplotype diﬀerences between donor and recipient
mice, allowing for the tracking of BM-derived cells within
the tumor. Donor BM cells expressed the endothelial marker
CD31 and were incorporated into the endothelial layer of
blood vessels within the tumor.
Further exploration using various transplant models
where BM-derived cells within the tumor were tracked by
ﬂuorescent dyes or by transgenically expressed GFP con-
ﬁrmed Bolontrade’s report of BM-derived endothelial cells
within Ewing’s tumor vasculature and expanded this ﬁnd-
ing to include BM-derived pericytes/vSMCs. While only a
small portion of the endothelial cells in Ewing’s sarcoma
tumor vessels are BM derived, a much larger portion of
the pericytes/vSMCs are BM derived. The pericytes/vSMC
component of the majority of the blood vessels in Ewing’s
sarcoma is a mosaic of BM-derived and locally derived cells,
indicating a combination of angiogenesis and vasculogenesis
[15–17]. TC71 Ewing’s sarcoma cells grown subcutaneously
in nude mice that had received GFP+ BM transplants were
used to demonstrate that BM-derived cells are intertwined
with locally derived cells in tumor vessels. Analysis of these
tumors revealed thick layers of GFP+ BM-derived cells sur-
rounding CD31+ endothelial cells. Costaining for GFP and
the pericyte/vSMC markers, desmin, alpha smooth muscle
actin (α-SMA), and platelet, derived growth factor receptor
beta (PDGFR-β), demonstrated that many of the GFP+
BM-derived cells also expressed pericyte/vSMC markers,
indicating that BM cells diﬀerentiate into pericyte/vSMC in
Ewing’s sarcoma in vivo [16]. Importantly, the GFP+ BM-
derived pericytes/vSMC were adjacent to and intertwined
with GFP−, locally derived pericytes/vSMC, indicating a
contribution from both local pericyte/vSMC proliferation
and BM cell diﬀerentiation. Recently, BM-derived cells were
also shown to be within the vasculature of a xenograft
model of Ewing’s sarcoma lung metastasis, indicating that
vasculogenesis may play a role in vascular formation in
metastases as well as primary Ewing’s tumors [18].
In addition to endothelial cells and pericytes/vSMC,
a small subpopulation of tumor inﬁltrating BM cells in
Ewing’s sarcoma are monocytes (CD14+) or macrophages
(F4/80+). However, these cells do not directly participate
in the formation of the vessel structure as they are found
in the center of the tumor away from the vessels [16].
These nonvascular BM-derived immune cells arise from
the Sca1−Gr1+ mouse BM or CD34− human progenitor
cell subpopulations, while Sca1+Gr1+ mouse BM or CD34+
human progenitor cells contribute to the endothelial cell
and pericyte/vSMC populations within the tumor [16].
The function of these macrophages in Ewing’s sarcoma is
unknownatthistime.Inothertypesoftumors,macrophages
have been demonstrated to play diverse roles including both
tumor-promoting and growth-inhibiting eﬀects. A subset of
tumor-associated macrophages has been demonstrated to
be induced by hypoxia to secrete angiogenic factors that
stimulate tumor vascular development [19, 20]. However,
the role of macrophages in vascular development in Ewing’s
sarcoma is not well studied and is beyond the scope of this
review.
3.VasculogenesisIsEssentialforEwing’s
SarcomaTumorGrowth
The BM-derived cell contribution to Ewing’s vessel develop-
ment is essential for tumor growth. Angiogenesis alone is
not suﬃcient to form a vascular network large enough to
support tumor growth. This was demonstrated by the use of
an MEKK3knockoutBMtransplant model where nude mice
(MEKK3 wild type) received MEKK3−/−BM transplants
[21]. MEKK3 is a mitogen-activated protein kinase kinase
kinase that is essential for early vascular formation. BM cells
lacking MEKK3 cannot participate in vascular formation. In
this model, local endothelial cells and pericytes/vSMC in the
recipient mice are MEKK3+/+ and can participate in vascular
formation while the BM cells, which are MEKK3−/−, cannot.
Thus, MEKK3−/− BM-transplanted mice have impaired
vasculogenesis but normal angiogenesis. The growth of both
TC71 and A4573 Ewing’s sarcoma tumors was signiﬁcantly
inhibited in MEKK3−/− BM-transplanted mice compared toSarcoma 3
tumors in control transplanted mice [21]. The inhibition of
tumor growth due to the absence of BM cell participation in
vascular formation demonstrates the necessity of vasculoge-
nesis for Ewing’s sarcoma tumor growth in vivo.
4.MolecularControlsofVasculogenesis
4.1. BM Cell Recruitment to the Tumor. BM cell partici-
pation in vasculogenesis is a complex, multistep process.
BM progenitors must be recruited to the tumor, retained
at sites of developing vasculature, and then be directed
to diﬀerentiate into endothelial cells and pericytes/vSMCs
(Figure 1). VEGF165 is one of the major chemotactic
stimulant for the recruitment of BM-derived cells to Ewing’s
tumors [22]. VEGF is highly expressed in primary human
Ewing’s tumors, the serum of Ewing’s patients, and Ewing’s
xenograft tumors [23, 24]. To demonstrate the chemotactic
properties of VEGF165,s h R N Aw a su s e dt os p e c i ﬁ c a l l y
inhibit the expression of VEGF165 (but not other VEGF
isoforms) in TC71 Ewing’s sarcoma cells, creating the stable
TC/siVEGF165 clone. Prior to the injection of TC/siVEGF165
cells, mice received BM transplants of CD34+ human cord
blood progenitor cells. This allowed for the tracking of
t h eB Mc e l l s ,a st h e yw e r eh u m a n .T C / s i V E G F 165 cells
g r o w ns u b c u t a n e o u s l yi nt h eC D 3 4 +-transplanted mice
formed smaller, slower-growing tumors than parental TC71
or TC/si control cells. Importantly, TC/siVEGF165 tumors
had decreased microvessel density and reduced numbers of
CD34+ BM-derived cells [25]. In subsequent studies, selec-
tive expression of VEGF165,V E G F 189,o rβ-gal control was
induced in TC/siVEGF165 tumors using adenoviral vectors.
Fluorescently labeled mouse BM cells were subsequently
injected into the tumor-bearing mice. Adenoviral VEGF165,
but not VEGF189 or β-gal, rescued tumor growth to a level
that was similar to wild-type TC71 tumors and caused
increased inﬁltration of BM-derived cells into the tumors.
These BM cells participated in tumor vascular formation
[22]. Together, these studies demonstrate the essential role
of VEGF165 in recruiting BM-derived cells to the tumor and
in the process of vasculogenesis [22].
The important role of VEGF165 in BM cell recruitment
and tumor growth suggests that VEGF may be a relevant
target for the treatment of Ewing’s sarcoma. Indeed, sub-
sequent studies using the MHC mismatch BM transplant
model demonstrated the eﬃcacy of the VEGFR2 antibody
DC101 for preventing BM cell migration into the tumor
and inhibiting the growth of Ewing’s sarcoma tumors in
vivo [26]. Tumors from mice treated with DC101 had
reduced numbers of BM-derived pericytes/vSMCs, reduced
microvessel density, and importantly, signiﬁcantly-inhibited
tumor growth [26].
While VEGF165 is chemotactic for BM cells, it also
stimulates the local angiogenesis process. The importance
of BM cells in the formation and expansion of tumor
vessels and the potential of these cells to rescue tumor
growth even in the absence of an angiogenesis stimulus was
further demonstrated by treating VEGF165 inhibited TC71
tumors (TC/siVEGF165) with stromal cell-derived factor-1
alpha (SDF-1α). SDF-1α is a chemoattractant for CXCR4+
BM progenitor cells, but has little or no eﬀect on local
angiogenesis and does not stimulate tumor cell proliferation.
Therefore treating VEGF165-inhibited tumors with SDF-
1α should increase BM cell migration into the tumor
area without stimulating local angiogenesis. Treatment of
TC/siVEGF165 tumors with intratumoral injections of an
adenoviral vector carrying the SDF-1α gene (Ad-SDF-1)
increased tumor expression of SDF-1α without increasing
VEGF165 [27]. In these studies, bilateral TC/siVEGF165 cells
were implanted into both ﬂanks of nude mice that had
received GFP+ BM transplants. Tumors were then treated
with intratumor injections of Ad-SDF-1 (right side tumors)
or Ad-control (left side tumors). Since the tumors were in
the same mouse, the host and BM cell pool were identical.
Diﬀerences in tumor growth or vascular morphology were
therefore secondary to the treatment of the tumors and
the diﬀerence in SDF-1α levels. Ad-SDF-1α tumors had
signiﬁcantly larger lumen-bearing vessels with increased
numbers of GFP+ BM-derived pericytes/vSMCs than Ad-
control treated tumors. In addition to increased vascularity
and BM-derived pericytes/vSMCs, Ad-SDF-1 rescued tumor
growth in the absence of VEGF165. Ad-SDF-1α-treated
tumors were larger than their Ad-control counterparts [27].
These data also reinforce the importance of BM-derived
pericytes/vSMCsfortumorgrowthinvivoandtheirabilityto
circumvent the antitumor activity of agents that solely target
VEGF.
4.2. BM Cell Diﬀerentiation. The process of vasculogenesis
requires steps beyond BM cell migration into the tumor.
Once BM cells are recruited to the tumor by VEGF165,t h e y
must diﬀerentiate into endothelial cells or pericytes/vSMCs
in order to participate in blood vessel formation and
help form a functional vessel. As previously stated, the
vast majority of vessel-associated BM-derived cells within
E w i n g ’ st u m o r sh a dd i ﬀerentiated into pericytes/vSMCs.
Pericytes/vSMCs have several functions relating to vessel
structural stability, regulation of blood ﬂow, and vessel
maturation [28–30]. Additionally, pericytes/vSMC provide
proliferation or quiescence signals to endothelial cells [30,
31]. Without pericytes/vSMC, vessels become leaky and less
functional and are more susceptible to regression [31, 32].
Understanding the signals that direct BM cell diﬀerentiation
into pericytes/vSMC may identify molecular targets that
are important for the formation of the BM-derived peri-
cytes/vSMC cell layer that can be targeted to impair tumor
vessel functionality which will subsequently inhibit tumor
growth.
Onepath wayfoundtobeimportantinthediﬀerentiation
of BM cells into pericytes/vSMC is the Notch signaling
pathway. The Notch family is an evolutionarily conserved
group of ligands and receptors that regulate diverse biologic
processes including cell fate assignment, stem cell mainte-
nance, and boundary formation during development [33].
The mammalian Notch family includes four heterodimeric
transmembrane receptors, Notch 1–4, and ﬁve transmem-
brane ligands, Jagged 1,2 and Delta likeligand 1, 3, 4(DLL1-
4) [33, 34]. Activation of the Notch pathway occurs by direct4 Sarcoma
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Figure 1: The steps for BM cell participation in tumor vessel development and expansion. (a) BM cell recruitment to the tumor. One major
chemoattractant for BM cell recruitment to the tumor is VEGF165.V E G F 165 is secreted by tumor cells to form a concentration gradient in
the circulation, which attracts BM cells. When VEGF165 is silenced by siRNA, the number of BM-derived pericytes/vSMCs within tumor
vasculature is signiﬁcantly reduced and tumor growth is inhibited. In the absence of VEGF165,S D F - 1 α can recruit BM-derived cells to the
tumor and rescue tumor growth. (b) Adhesion and Extravasation. When BM cells reach the developing tumor vasculature, they must adhere
to the endothelial cell wall and extravasate to the extraluminal side of the vessel. (c) Diﬀerentiation. Once a BM cell has extravasated to the
extraluminal side of a blood vessel within the tumor, it must diﬀerentiate from an immature progenitor cell into a mature pericyte/vSMCs,
endothelial cell, or nonvascular cell. DLL4-Notch signaling is critical for BM cell diﬀerentiation into periyctes/vSMCs in Ewing’s sarcoma.
BM cells express DLL4 as well as Notch receptors. When DLL4 is inhibited by shRNA or by a DLL4-neutralizing antibody, the number of
BM-derived pericytes/vSMCs within the tumor is signiﬁcantlyinhibited and tumor growth is reduced.
contact between a membrane bound ligand onone cell and a
membrane bound receptor on a neighboring cell [34].
The Notch ligand Delta like ligand 4 (DLL4) is essential
for the formation of BM-derived pericytes/vSMC in Ewing’s
sarcoma in vivo [35]. DLL4 is expressed by the BM-derived
pericytes/vSMC in Ewing’s tumors [35]. This was demon-
strated using TC71 or A4573 Ewing’s sarcoma xenografts
and a GFP BM transplant model. In both A4573 and TC71
tumors, immunohistochemical analysis demonstrated co-
localization between DLL4 and GFP, as well as DLL4 and the
pericyte/vSMC markers desmin, NG2, and α-SMA. Twelve
of fourteen human Ewing’s sarcoma samples, including
metastatic lesions, had similar patterns of DLL4 expression
by perivascular cells. DLL4 inhibition by shRNA or by the
DLL4 neutralizing antibody YW152F signiﬁcantly reduced
the number of BM-derived pericytes/vSMC within the
tumor, reduced vessel functionality (indicated by increased
hypoxia), and inhibited tumor growth in vivo [35, 36]. The
loss of BM-derived pericytes/vSMC after DLL4 inhibition
substantiates the critical role of DLL4 in the formation of
BM-derived pericytes/vSMCs, and a functional vasculature.
DLL4 may therefore be a therapeutic target for the treatment
of patients with Ewing’s sarcoma, as indicated by the tumor
growth inhibition in tumors when DLL4 was blocked.
5.ClinicalTrialsUsing
Vascular-TargetingAgents
A phase I trial in the Children’s Oncology Group (COG)
examining bevacizumab, a monoclonal antibody that
inhibits VEGF-A signaling, as a single agent was completed.
Inthisstudy,bevacizumabwasadministered everytwoweeks
in 28-day courses to children with solid refractory tumors,
including 5 patients with Ewing’s sarcoma. Two of the 5
had stable disease for greater than 4 months, and one had
stable disease for two months. No dose-limiting toxicities
occurred [37]. Bevacizumab is already FDA approved for use
in patientswitha varietyofcancertypes,includingcolorectal
cancer and glioblastoma multiforme. Concerns over toxicity
recently prompted a review of fatal adverse eﬀects (FAEs)
related to bevacizumab, in which the authors concluded that
while bevacizumab is associated with increased FAEs when
combined with taxane-or platinum-based chemotherapies
(3.3% v 1.0%), it is not associated with increased FAEs when
used in combination with other chemotherapies (0.8% v
0.9%) [38].
InadditiontoVEGF,DLL4iscurrentlybeingevaluatedas
atherapeutictargetforthetreatment ofsolidtumors,includ-
ing Ewing’s sarcoma. A phase I trial of the DLL4-neutralizingSarcoma 5
antibody REGN421 is currently underway (ClincalTrials.gov
id: NCT00871559). A trial evaluating REGN421 in pediatric
populations is planned.
Itisunlikelythatantivasculartherapieswillbeeﬀectiveas
single agents against bulk disease. In most preclinical models
evaluating VEGF-targeting therapies in Ewing’s xenografts,
tumor growth was stopped or slowed by treatment, but
tumors did not regress and often rebounded after cessation
of therapy [24, 39]. One notable exception demonstrated
signiﬁcant regression of SK-NEP-1 primary Ewing’s tumors,
decreased numbers of lung metastases, and smaller lung
metastases in mice treated with VEGF-Trap [40]. A phase
I trial using VEGF-Trap, a soluble VEGF decoy receptor, is
in progress (Protocol id ADVLO714). However, vascular-
targeting therapies will most likely be useful either in
combination with chemotherapy or radiation therapy, or
as adjuvant therapy following chemotherapy or surgery.
While inhibition of DLL4 leads to ablation of the functional
vascularnetwork,inhibitionofVEGFcan,insomecases,lead
toa transient stageofvesselnormalization. Duringthisstage,
vessels are actually more eﬃcient at delivering oxygenated
blood. This “vessel normalization” stage may be useful
for preparing tumors for radiation therapy, which works
most eﬃciently on well-oxygenated cells, or for combination
therapy with chemotherapeutic agents, which would be
deliveredmoreeﬃcientlyduringthisphase.Itisimportantto
note, however, that long-term anti-VEGF therapy eventually
leadstosuchextensivevesselpruningthateven“normalized”
vessels are eradicated and tumor growth is inhibited [41].
For an in-depth review of the subject, see the review by De
Bock et al. [41]. A phase II trial combining bevacizumab
with combination of chemotherapies has recently been
discontinued after accruing only 10% of the original target
number of participants, making conclusions on the eﬃcacy
of bevacizumab and chemotherapy in Ewing’s sarcoma
diﬃcult to achieve at this time (Children’s Oncology Group
Trial COG-AEWS0521).
As an alternative to using vascular-targeting agents con-
currently with chemotherapy, vasculogenesis inhibitors
(such as VEGF or DLL4 inhibitors) may be useful after
chemotherapy is completed. After cytotoxic therapy, the
number of circulating BM-derived progenitor cells increases
[42]. As evidenced by the studies described above using
SDF-1α, these circulating BM cells may gain access to the
tumor and aid in the expansion of residual tumor cells or
microscopic metastases by contributing to the formation of
a vascular system to feed the metabolic needs of proliferating
tumor cells. Therefore, inhibition of VEGF or DLL4, both of
which areimportant for BMcellparticipation in vasculogen-
esis, afterchemotherapy mayprovetobeusefulinpreventing
disease relapse or metastasis.
6.Conclusion
The contribution of BM-derived cells to the endothelial cell
and pericyte/vSMCpopulations within Ewing’s sarcoma vas-
culaturehasnowbeendemonstratedusingmultiplemethods
to track BM-derived cells within the tumor. Additionally,
genetic targeting of vasculogenesis, but not angiogenesis, via
MEKK3 knockout has shown that vasculogenesis is essential
f o rt h eg r o w t ho fE w i n g ’ ss a r c o m ain vivo [21]. Without
vasculogenesis, tumor growth is signiﬁcantly inhibited.
Agents targeting VEGF, the major chemotactic stimulus for
recruiting BM cells to the tumor, and DLL4, an important
molecular signal for the diﬀerentiation of BM-derived cells
into pericytes/vSMCs, are currently being evaluated for
clinical eﬃcacy. Initial studies suggest that SDF-1α may also
be an important target for the inhibition of vasculogenesis,
particularly in tumors that have developed resistance to
VEGF-targeted therapy.
While signiﬁcant progress has been made in under-
standing the process of vasculogenesis in tumor biology
over the past decade, several questions remain. Further
understanding of the regulation of vasculogenesis in Ewing’s
sarcoma will most likely be required for the development of
newtherapies.Forexample,themolecularsignalscontrolling
BM cell adhesion to tumor vasculature and extravasation
to the extraluminal side of blood vessels may also provide
therapeutic targets for inhibiting vasculogenesis. Addition-
ally, while DLL4-Notch signaling is important for BM cell
diﬀerentiation into pericytes/vSMCs, the relative contribu-
tion of other pericyte/vSMC diﬀerentiation factors, such as
transforming growthfactor beta(TGF-β)a n dP DG F R - β,h a s
not been evaluated in Ewing’s sarcoma. Further laboratory
studies of the molecular controls of BM cell participation in
vasculogenesis as well as clinical studies of speciﬁc vascular-
targeting agents are the next steps in assessing the potential
for using this therapeutic approach in the treatment of
patients with Ewing’s sarcoma.
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